| Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ... New England Journal of Medicine 386 (4), 351-363, 2022 | 425 | 2022 |
| Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults M Sugidono, M Lo, R Young, K Rosario, Y Jung, CY Huang, Y Sheng, ... Transplantation and Cellular Therapy 27 (4), 344. e1-344. e5, 2021 | 13 | 2021 |
| 1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world … R Dziadziuszko, Q Zhang, X Li, SM Paul, M Sugidono, S Mocci, ... Annals of Oncology 31, S845-S846, 2020 | 3 | 2020 |
| Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study. B Hu, PM Reagan, LH Sehn, JP Sharman, M Hertzberg, H Zhang, AI Kim, ... Journal of Clinical Oncology 41 (16_suppl), 7518-7518, 2023 | 2 | 2023 |
| Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and … JW Friedberg, CA Thompson, M Trněný, F Morschhauser, G Salles, ... Blood 140 (Supplement 1), 6623-6626, 2022 | 1 | 2022 |
| Patient-versus clinician-reported symptoms in the POLARIX study. CA Thompson, N Mehta-Shah, C Flowers, GA Salles, H Tilly, NS Chua, ... Journal of Clinical Oncology 41 (16_suppl), 12100-12100, 2023 | | 2023 |
| Redefining Polypharmacy in Older Adults and Understanding the Impact on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes M Sugidono, M Lo, R Young, K Rosario, Y Jung, CY Huang, Y Sheng, ... ACCP Virtual Poster Symposium, May 26 and 27, 2020, 2020 | | 2020 |
| Redefining Polypharmacy in Older Adults and Understanding the Impact on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes PHMLP Patient | | |
